Objective: Evaluation of response of granulocyte macrophage colony stimulating factor (GM-CSF) on acute radiation toxicity profile in head and neck squamous cell carcinoma.
INTRODUCTION
reddening of mucosa becomes evident. After an additional 10 to 20 Gy, small white areas of pseuHead and neck cancers constitute a major oncodomembrane begin to appear. In their early de logical problem in the Indian population. These velopment, these patches tend to be scattered cancers top the list in sitewise distribution. There throughout the treatment field. As the treatment were 25.1% registered Head and Neck cancer continues, the patches begin to coalesce, lead cases in a hospital based cancer registry in 1998.
ing to confluent mucositis. [5] Acute mucositis is Its frequency was no different from those seen the result of hypoplasia of squamous epithelium over the years 1984-98 i.e. 27%. [1] due to sterilization of mucosal stem cells and in hibition of proliferation of transit cells. [6] Evidence Radiation therapy remains the mainstay of treathas emerged to suggest that mucositis develops ment in the management of head and neck canas a series of dynamic interactions that begin in cers. It is offered to nearly 75% of all head and the epithelium but then progress to involve other neck cancers with either curative or palliative tissue components. Sonis et al have proposed that intent, alone or as a part of multimodality apthis process can be thought of as occuring in five proach. [2] Oropharyngeal mucositis is a frequent stages or phases:initiation, message generation, side effect of radiotherapy for head and neck cansignal amplification, ulceration, and healing. [7] cer. [3] It represents an important clinical problem The initiation phase involves direct damage to as there is associated severe pain, the need for DNA and other cellular components that occurs parenteral nutrition, risk of mucosal infection and immediately following exposure to radiation or subsequent septicemia.
[4] By 20-30 Gy, with standchemotherapy. These treatments generate reac ard fractionation delivered at 1.8 to 2.0 Gy/day, tive oxygen species (ROS), free radicals that can cause DNA strand breaks in the epithelium and submucosa and initiate a cascade of other down stream biological events. In the next stage-upregulation and message gen eration -transcription factors are activated that affect a number of genes controlling protein synthesis and cell signaling. Signal amplification, the third stage, consists of feedback loops that further increase the number and level of activating signals. Pro inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), which are secreted fol lowing radiation or chemotherapy damage, not only directly result in tissue injury but also further increase the activity of other signaling factors such as NF-kBand mitogen acti vated protein kinase (MAPK). [8] The net result is an ongoing cycle of amplification of injury that persists well after the initial insult of radiation therapy or chemotherapy. Inter estingly, despite all these cellular changes occurring dur ing the initial stages of mucositis, few symptoms are ap parent. The fourth stage, ulceration, involves penetration through the epithelium into the submucosa. The ulcerated surface can then be colonized by oral bacteria, producing toxins and additional inflammatory cytokines (from acti vated macrophages) and angiogenic factors. This ulcera tive phase is primarily responsible for the main clinical symp toms of mucositis (pain, inflammation, and loss of function) and is associated with higher costs (increased drug use and hospitalization). The final stage in the pathobiology of mu cositis is healing, Epithelial cells, under control of signals secreted by the extracellular matrix, migrate, grow and dif ferentiate to form a wound. These signals are then downregulated to avoid hyperplasia. With the healing proc ess under way, symptoms begin to abate. Severe mucositis may lead to interruption of planned course of radiotherapy. Prolongation of overall time of radiation has an adverse ef fect on radiocurability of head and neck squamous cell car cinoma. [9, 10, 11] Throughout the last two decades there have been many attempts to identify remedies to prevent or at least amelio rate symptoms of oral mucositis, [12] but none has resulted in satisfactory outcome. Granulocyte-macrophage colony stimulating factor (GM-CSF) has been shown to enhance a number of cellular functions which are essential for wound healing, including activation of neutrophils,monocytes and macrophages, migration of epithelial cells, proliferation of keratinocytes and modulation of fibroblast phenotype. [13, 14, 15] The role of cytokines, like GM-CSF, has been investigated for mucosal protection during cytotoxic chemotherapy also. [16] [17] Administration of IL-1 during fractionated radio therapy in C3H/K mice showed protection of lip mucosa and tongue from acute radiation reaction. [18, 19] A pilot study showed that GM-CSF administration concurrently with con ventional fractionated radiotherapy was feasible without significant toxicity. It showed that the acute side effects of radiotherapy namely mucositis, pain and functional impair ment were nil to minimal in head and neck cancers. [20] Also, clinical studies of GM-CSF have found no stimulation of tumor growth. [21] Based on these experiences, we planned to carry out a study to further explore the role of GM-CSF in radiation mucositis in head and neck cancers at our centre.
PATIENTS AND METHODS

Eligibility Criteria
• Adult patients.
• Histologically proven head and neck squamous cell car cinoma. • Karnofsky's performance status > 70 • Complete blood counts, liver function tests, renal func tions tests and blood sugar tests were within normal limits.
• No history of prior radiation therapy or cytotoxic chemo therapy.
• No autoimmune disease.
Characteristics of the Patients
Thirty three patients were treated with definitive or post operative adjuvant radiation therapy from Jan 2000 to Dec.2002. There were 8 female and 25 male patients. The median age was 50 years (range 21 to 70 years). According to AJCC staging 9 patients had stage I and 24 had stage II malignancy. Twenty nine patients were found to use tobacco.
Subject Habits
Location Patients received external beam radiation with two paral lel opposed fields using telecobalt gamma rays at 80 cms SSD. Twenty seven patients were treated definitively with teletherapy and six received postoperative adjuvant exter nal beam radiation. The average dose delivered to patients in radical group was 66.7Gy and in adjuvant group was 57.2Gy in conventional fractionation. The patients were treated with shrinking fields after 40Gy and mucositis was analysed all the time in the reduced field of treatment. They received 50 Gy to the whole field, though the spinal cord was shielded at 40 Gy. The treatment volume was then re duced and dose was escalated.The mean field size was 110.9 cm2. None of the patients received concurrent chemo therapy.
All patients underwent dental prophylaxis in the form of scaling and fluoride application. Dental cavity filling and extraction were done, where indicated, prior to radiation therapy. Those using artificial dentures were advised not to wear the same during the treatment. Patients were in structed to maintain strict oral hygiene using a soft baby toothbrush and flouride toothpaste. They were counselled against using mouthwashes containing phenol or alchohol, tobacco, alcoholic beverages, very hot and cold food and spicy food. No intraoral tumor ablative procedures, alter ing the mucosal surfaces, were performed on the subjects. None of the patients had intercurrent ailments or preexist ing pathologies that affected mucosal integrity. None of the patients had gap in radiation therapy. Same examiner graded all mucosal reactions, pain and functional impairement. All the patients were treated according to the ethical guidelines followed routinely in the hospital.
Administration of GM-CSF
The patients were given Injection GM-CSF (Leucomax®) 100 mcg subcutaneously per day after reconstitution. The sites of injection were rotated. The drug was started when one of the following criteria was observed. a) Patchy fibrinous mucositis. b) Pain not responding to step I pain killers (WHO step lad der). c) Difficulty in swallowing semisolid food.
GM-CSF was given for six consecutive days, excluding the days, when radiation was not delivered. When the above signs and symptoms persisted, its administration was pro longed till there was a subjective or objective response. Subjective response was assessed by scoring dysphagia and pain. Grading of mucositis was done based on the objec tive response. Dysphagia, pain and mucositis were graded according to CTC version 2.0 [ Table 1 ]. The mean total dose delivered to the patients was 731.2 mcg (20 patients re ceived 600 mcg, 10 patients received 900 mcg and 2 pa tients received 1200 mcg). Weekly evaluation was done to assess mucosal reaction, pain and dysphagia. 
RESULTS
Acute Toxicity Profile During Radiation Therapy
Functional Impairment Dysphagia to semisolid food (grade 2) was seen in 7 out of 27 definitively treated patients by the end of seven weeks of radiation therapy. None of the patients experienced dys phagia worse than grade 3 during the whole treatment [ Table 2 ].
In the third week of radiation therapy 63.63 % & 36.36% patients developed grade 1 and grade 2 mucositis respec tively. It improved with the administration of GM-CSF, as is evident [ Table 3 ]. Confluent mucositis was seen in three and four patients in the fourth and fifth week of treatment re spectively. One patient developed oral candidiasis. She re sponded to 20 days' course of oral fluconazole.
Pain
With the use of GM-CSF the decreased incidence and sever ity of mucositis has lead to grade 2 pain in 36.36%, 24.24%, 9.09% & 29.62% paients in 4th to 7th week respectively. Grade 3 pain was experienced by four patients [ Table 4 ]. They were unable to swallow even liquids hence, nasogastric feeding was required.
Weight
Pretreatment & posttreament weight was recorded. None of the patients lost more than 10% weight. Less than 10% weight loss was seen in 21 (63.6%) patients . Eleven pa tients had no weight loss and one patient gained weight. The mean weight loss was 1.94%.
Response Assessment and Survival on Completion of Radiation Therapy
The response was not assessable in 18.1% (6) patients who received postoperative adjuvant radiation therapy. Com plete response was seen in 88.88% (24/27) patients who received definitive RT. Twenty eight patients were clinically controlled till May 2003, one patient had progressive dis ease and died 7 months after completion of radiation, three patients recurred locally, and one patient died of an unre lated cause 13 months after the treatment.
Side effects of GM-CSF
The side effects of the drug were minimal. Two patients (6%) complained of itching and developed erythema at the site of injection which responded to oral antihistaminics.
DISCUSSION
Oral mucositis continues to afflict all the patients who re ceive radiation therapy. Till date, there is not a single agent that is considered to be "gold standard" to prevent or treat oral mucositis. [22] A review published by Andy Trotti et al [23] confirms the high incidence (97%) of mucositis in patients receiving RT in analyses of 33 studies (n = 6181 patients). The rates of grade 3 mucositis was higher in RT altered fractionation (65%) than in RT conventional group (49%), as was the rate of grade 4 mucositis (17 v/s 5%, respectively). RTOG has recently reported severe mucositis in 25% in con ventional RT group and 41-47% in accelerated fractionation group. [24] Because of more rapid cellular turnover in mucosa it exhib its the radiation induced damage rapidly. [5] Al-Tikriti et al reported mucosal plaque formation and ulceration in most patients at 3 to 4 weeks after initiation of radiotherapy. [25] EORTC randomized trial of conventional and hyperfractionated radiotherapy in oropharyngeal carcinoma observed 42% grade II and 49% grade III mucositis in 2 Gy fractionation arm. [26] GM-CSF protects neutrophil from apoptosis and prolongs its half -life. [27] It also protects cap illary endothelial cells from radiation induced apoptosis. [28] Mammalian cells respond to oxidative stress of radiation by activating genes that encode GM-CSF and Interleukin -1. [29] Secretion of Interleukin -1 is observed at the inflammatory site by the colony stimulating factor. [21] Our trial suggests mucosal protection in all the patients as none of the patients suffered grade IV mucositis inspite of delivering 66.7Gy median dose to 110.9 cm2 tissue. Grade III mucositis was experienced by 9.09% and 12.12 % pa tients in the forth and fifth week respectively. It was ob served that besides mucosal healing, GM-CSF also protects the mucosa from further radiation induced damage as the drug was discontinued during radiation once the patient showed symptomatic and subjective improvement. The patients were able to complete the planned radiation therapy without any interruption. Since the incidence and severity of mucositis was less in our study, there was a de creased incidence of oral pain. The overall incidence of dys phagia was decreased, which resulted in 1.94% mean weight loss.
Minimal side effects of the drug were observed in our study. Since the patients were already on NSAIDS, they did not suffer from flu like symptoms. In the literature the quan tity of drug used in a patient ranges from 1 to 5 mcg/kg./ day for the complete duration of radiation in I/V, S/C or topi cal form. [20, 30, 31, 32, 33, 34] In different studies drug was initiated at different days ranging from day 1 to day 11 of radiation therapy [ Table 5 ].
Large amount of GM-CSF has been used in the above stud ies and the cost involved has been discussed with concern. In our study we have administered GM-CSF when the pa tient became symptomatic and / or started developing fibrinous mucositis and not from the beginning or after 20 Gy. In our opinion since the drug is expensive, route of ad ministration is invasive and it has a toxicity profile, though low, it should be used judiciously and in smallest possible dose which benefits the patient. S/C = Subcutaneous, LA = Local Administration, Sympt = On apperance of the symptoms, D = Day CONCLUSIONS GM-CSF is able to provide subjective response within 24 hours and objective response in less than a week. There is therefore, no need to give it in asymptomatic patients. Larger double blind randomized trials are recommended to find out the optimum dose and timing of initiating and stop ping the drug during RT.
